What is the appropriate management for a patient with low ferritin, low iron saturation, high TIBC, elevated hemoglobin and hematocrit, and thrombocytosis?

Management Recommendation

This patient has clear iron deficiency (ferritin 6.7 μg/L) with paradoxical polycythemia (hemoglobin 17.5 g/dL, hematocrit 52.6%) and reactive thrombocytosis (platelets 472), requiring immediate investigation for an underlying myeloproliferative disorder—particularly polycythemia vera—before initiating iron replacement therapy.

Critical Diagnostic Considerations

The laboratory constellation is physiologically contradictory and demands urgent evaluation:

• Ferritin 6.7 μg/L: Severe iron deficiency (normal >15-30 μg/L) 1, 2
• TIBC 468 mg/dL: Elevated, confirming iron deficiency
• Iron saturation 22%: Low-normal, consistent with depleted iron stores
• Hemoglobin 17.5 g/dL with hematocrit 52.6%: Polycythemia (not anemia)
• Platelets 472: Thrombocytosis

This combination strongly suggests polycythemia vera (PV) with concurrent iron deficiency, a well-recognized phenomenon where iron deficiency is nearly universal in PV patients 3. The iron deficiency in PV results from dysregulated iron metabolism and increased erythroid consumption, not from blood loss alone.

Immediate Next Steps

1. Rule Out Myeloproliferative Neoplasm

Order JAK2 V617F mutation testing immediately 3. The presence of polycythemia with iron deficiency is pathognomonic for PV until proven otherwise. If JAK2 V617F is negative, proceed with JAK2 exon 12 mutation testing.

Additional required testing:

• Erythropoietin level (expected to be low in PV)
• Bone marrow biopsy if JAK2 mutations are negative but clinical suspicion remains high
• Complete metabolic panel to assess for secondary causes of polycythemia

2. Assess Thrombotic Risk

The thrombocytosis (472) combined with polycythemia creates significant thrombotic risk. Patients with iron deficiency and thrombocytosis have a 2-fold increased risk of thrombosis compared to iron deficiency alone (15.8% vs 7.8%) 4. The elevated platelet mass index correlates strongly with decreasing hemoglobin in iron deficiency states.

Check for:

• History of thrombotic events (arterial or venous)
• Cardiovascular risk factors
• Symptoms of hyperviscosity (headache, visual disturbances, dizziness)

Management Algorithm

If Polycythemia Vera is Confirmed:

Do NOT initiate iron replacement until hematocrit is controlled 3. Iron repletion in untreated PV will worsen polycythemia and increase thrombotic risk.

1. Therapeutic phlebotomy: Target hematocrit <45% to reduce thrombotic complications
2. Cytoreductive therapy (hydroxyurea or interferon) for high-risk patients (age >60 or prior thrombosis)
3. Low-dose aspirin (81-100 mg daily) unless contraindicated
4. Defer iron supplementation: Iron deficiency actually limits erythrocytosis in PV. Cytoreductive therapy works more effectively in iron-deficient PV patients 3

If Polycythemia Vera is Excluded:

Investigate alternative causes of polycythemia with iron deficiency:

• Cyanotic congenital heart disease: The combination of extreme erythrocytosis with iron deficiency is well-documented 5. Check oxygen saturation, echocardiogram
• Chronic hypoxemia: Sleep apnea, chronic lung disease, high altitude
• Renal pathology: Inappropriate erythropoietin production
• Smoking-related polycythemia

Once secondary polycythemia is addressed, proceed with iron replacement.

Iron Replacement Strategy (Only After Excluding/Treating PV)

Following current guidelines 1, 2:

Oral iron supplementation:

• Ferrous sulfate 325 mg (65 mg elemental iron) or equivalent ferrous fumarate/gluconate
• Take on empty stomach with 500 mg vitamin C to enhance absorption
• If gastrointestinal side effects occur, consider lower-dose preparations (28-50 mg elemental iron) or ferrous bisglycinate
• Recheck complete blood count, ferritin, and iron studies at 8-10 weeks

Intravenous iron indications:

• Malabsorption (celiac disease, inflammatory bowel disease)
• Intolerance to oral iron despite formulation changes
• Need for rapid repletion
• Failure of oral iron after 8-10 weeks

Target ferritin >30 μg/L for adults 6, though in the context of chronic disease, aim for >45 μg/L 1.

Critical Pitfalls to Avoid

1. Never assume this is simple iron deficiency anemia: The elevated hemoglobin/hematocrit makes this impossible. Missing PV diagnosis leads to inappropriate iron supplementation and increased thrombotic risk.

2. Do not give iron before controlling polycythemia: This will exacerbate erythrocytosis and thrombotic complications 3.

3. Monitor for thrombosis closely: The combination of thrombocytosis and polycythemia creates substantial risk. Consider thromboprophylaxis in high-risk situations 4.

4. Recognize that ferritin <15 μg/L has 99% specificity for iron deficiency 2, so the iron deficiency is real despite the polycythemia.

Gastrointestinal Evaluation

Even with polycythemia, investigate potential gastrointestinal blood loss contributing to iron deficiency 1, 2:

• Upper endoscopy and colonoscopy if age >50 or alarm symptoms present
• Celiac serology (tissue transglutaminase IgA)
• H. pylori testing
• Assess for occult bleeding, especially if JAK2 mutations are negative

The British Society of Gastroenterology recommends investigation at any level of iron deficiency when clinically appropriate, particularly with ferritin <45 μg/L 2.